Market Overview

Obalon to Host Corporate Strategy Update Call with Investors and Analysts on September 10, 2018

Share:

SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to host a Corporate Strategy Update conference call and simultaneous webcast on September 10, 2018 at 10am Eastern Time (7am Pacific Time). The call is intended to provide investors and analysts with lessons learned during the first 18 months of US commercialization of the Obalon Balloon System, management's revised strategy based on those learnings, and metrics upon which effectiveness of the revised strategy will be measured.

Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 8597517.  Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event.  The conference call will also be webcast live at:  https://edge.media-server.com/m6/p/azz9fe99.

An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics website located at http://investor.obalon.com in the "News & Events" section. 

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ: OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

For Obalon Therapeutics, Inc.

Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com

Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 4220
mdriscoll@evolvemkd.com

Primary Logo

View Comments and Join the Discussion!